Every one of those 1 sits in a single category, market-trends. Adaptive Biotechnologies is most often covered alongside Julie Rubinstein, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Adaptive Biotechnologies, all published on March 14, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Adaptive Biotechnologies
Every one of those 1 sits in a single category, market-trends. Adaptive Biotechnologies is most often covered alongside Julie Rubinstein, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Adaptive Biotechnologies, all published on March 14, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Adaptive Biotechnologies. Shared-story counts are live from our verified record — not editorial picks.
Adaptive Biotechnologies (NASDAQ: ADPT) executives Julie Rubinstein and Susan Bobulsky have sold a combined 60,398 shares, signaling a notable period of insider liquidation. The transactions occur as the company continues to navigate the competitive landscape of immune-driven diagnostics and MRD monitoring.